Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep Ltd is advancing its product candidate, eftilagimod alfa (efti), through a registrational Phase three clinical trial for first-line non-small cell lung cancer (1L NSCLC), demonstrating significant efficacy improvements in patients with lower PD-L1 expression. The drug has shown to increase overall response rates in less responsive populations, specifically boosting the ORR by 22.2% over historical rates, highlighting its potential to enhance treatment outcomes. Additionally, efti's strong patent portfolio and its capacity for combinability with existing therapies present opportunities for Immutep to expand its influence within the competitive oncology market.

Bears say

Immutep Ltd's stock outlook is negatively impacted by the declining confidence in its lead product candidate, eftilagimod alfa (efti), following underwhelming clinical results that have led to a reduced probability of success in non-small cell lung cancer (NSCLC) to 30%. The overall efficacy results from the INSIGHT-003 trial are anticipated to be inferior compared to historical benchmarks, particularly due to a higher proportion of patients with low tumor proportion scores (TPS<1%), which may exacerbate concerns around treatment effectiveness. Additionally, the mixed efficacy results from LAG-3 antagonists in lung cancer contribute to a perceptual headwind, as these therapies are not widely regarded as transformative, further diminishing investor confidence.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.